1 results match your criteria: "10 Gustave Roussy Cancer Campus and University of Paris-Saclay[Affiliation]"
Purpose: KEYNOTE-158 ( ClinicalTrials.gov identifier: NCT02628067) is a phase II basket study investigating the antitumor activity and safety of pembrolizumab in multiple cancer types. We present interim results from patients with previously treated advanced cervical cancer.
View Article and Find Full Text PDF